<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557007</url>
  </required_header>
  <id_info>
    <org_study_id>2017/9660</org_study_id>
    <nct_id>NCT04557007</nct_id>
  </id_info>
  <brief_title>Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients</brief_title>
  <acronym>Oncomabs</acronym>
  <official_title>Drug Concentration Monitoring of Pembrolizumab in Treatment-naive Non-Small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study explores associations between drug trough-levels and clinical&#xD;
      outcomes in Non Small Cell Lung Cancer (NSCLC) patients treated with immunotherapy&#xD;
      (pembrolizumab) either alone or combined with chemotherapy. Through-levels of pembrolizumab&#xD;
      will be examined in blood samples collected during the first-line treatment period. In&#xD;
      addition T-cell responses in peripheral blood and anti-drug antibodies will be monitored.&#xD;
      Results of drug trough-levels and T-cell responses will be linked to clinical outcome. 250&#xD;
      patients with NSCLC will be enrolled in this trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response</measure>
    <time_frame>3 months</time_frame>
    <description>Radiological response (Partial response/stable disease/Complete response)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events &gt;= 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-1 Expression on CD-8 T-cells</measure>
    <time_frame>First 3 months</time_frame>
    <description>Proliferation of PD-1 Expression CD-8 T-cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years observation</time_frame>
    <description>Overall survival related to drug trough-level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Radiological evaluation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pembrolizumab clearance</measure>
    <time_frame>3 months</time_frame>
    <description>mg/L</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Treatment-naive NSCLC patients</arm_group_label>
    <description>Treatment-naive NSCLC patients receiving immunotherapy (pembrolizumab) alone or in combination With chemotherapy divided in groups based on treatment administered. Clinical information will be gathered at start of treatment and at evaluations every 3rd month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Drug trough-level will be measured in patients on Pembrolizumab with or without additional chemotherapy in routine care.</description>
    <arm_group_label>Treatment-naive NSCLC patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and full blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        NSCLC patients With Advanced disease elligible for routine treatment With immunotherapy&#xD;
        alone or in combination With chemotherapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be &gt; 18 years and must voluntary sign an informed consent&#xD;
&#xD;
          -  Treatment-na√Øve patients with advanced NSCLC receiving immunotherapy alone&#xD;
             (pembrolizumab) or combined with chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any anti-cancer therapy &lt; 6 months prior to inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ragnhild Nome, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ragnhild Nome, MD</last_name>
    <phone>+4798602658</phone>
    <email>ragnom@ous-hf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Olavs University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arne Kildahl-Andersen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Ragnhild Nome</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

